CoChat

CipA mediates complement resistance of Acinetobacter baumannii by formation of a Factor I-dependent quadripartite assemblage

Open access

Preprint — published as 10.3389/fimmu.2022.942482

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Abstract

Multidrug-resistant Acinetobacter baumannii is known to be one of the leading pathogens that cause severe nosocomial infections. To overcome eradication by the innate immune system during infection, A. baumannii developed a number of immune evasion strategies. Previously, we identified CipA as a plasminogen-binding and complement-inhibitory protein. Here we show that CipA strongly inhibits all three complement activation pathways and interacts with key complement components C3, C3b, C4b, C5, Factor B, Factor D, and in particular Factor I. CipA also targets function of the C5 convertase as cleavage of C5 was impaired. Systematic screening of CipA variants identified two separate binding sites for C3b and a Factor I-interacting domain located at the C-terminus. Structure predictions using AlphaFold2 and binding analyses employing CipA variants lacking Factor I-binding capability confirmed that the orientation of the C-terminal domain is essential for the interaction with Factor I. Hence, our analyses point to a novel, Factor I-dependent mechanisms of complement inactivation mediated by CipA of A. baumannii . Recrutiment of Factor I by CipA initiates the assembly of a quadripartite complex following binding of either Factor H or C4b-binding protein to degrade C3b and C4b, respectively. Loss of Factor I binding in a CipA-deficient strain, or a strain producing a CipA variant lacking Factor I-binding capability, correlated with a higher susceptibility to human serum, indicating that recruitment of Factor I enables A. baumannii to resist complement-mediated killing. Significance Statement: The Gram-negative bacterium Acinetobacter baumannii causes severe nosocomial infections and has developed various immune evasion strategies to overcome complement. The mechanisms how Acinetobacter baumannii successfully circumvents complement-mediated bacteriolysis are still poorly understood. Here, we show that the plasminogen-binding and complement inhibitory protein CipA terminates all three complement activation pathways. We describe a novel mechanism by which CipA cleaves the key complement components C3b and C4b in the presence of Factor H and C4b-binding protein by formation of a novel Factor I-dependent quadripartite complex. CipA, which has recently been successfully used for vaccination approaches, might represent an attractive target for the development of novel therapeutic interventions to block disorders with excessive hyperinflammatory complement activation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2022.02.17.480811

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Assessment of the inhibitory capacity of CipA and CipA variants on activation of the AP and CP. Schematic representation of N- and C-terminal deletion CipA variants and structure predictions generated by using AlphaFold2.0 (A). Deletions are as follows: CipA ΔQ19-Q144 removes the whole META1 domain (green), CipA ΔL154-K369 removes the META2 (orange) and DUF4377 (blue) domains, while the CipA ΔQ291-K369 deletion removes most of the DUF4377 domain. Schematic representation of CipA variants carrying single and multiple deletions or substitutions (in red letters) (D). WiELISA was performed to assess the inhibitory capacity of CipA deletion variants on the AP (B, E) and CP (C, F). NHS pre-incubated with the purified CipA proteins or BSA (500 nM for AP and 2.5 µM for the CP) were added to microtiter plates immobilized with LPS (AP) or IgM (CP). Formation of the MAC was detected by using a monoclonal anti-C5b-9 antibody. Data represent means and standard deviation of at least three different experiments, each conducted in triplicate. ****, p ≤ 0.0001, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%).
Figure 1 Assessment of the inhibitory capacity of CipA and CipA variants on activation of the AP and CP. Schematic representation of N- and C-terminal deletion CipA variants and structure predictions generated by using AlphaFold2.0 (A). Deletions are as follows: CipA ΔQ19-Q144 removes the whole META1 domain (green), CipA ΔL154-K369 removes the META2 (orange) and DUF4377 (blue) domains, while the CipA ΔQ291-K369 deletion removes most of the DUF4377 domain. Schematic representation of CipA variants carrying single and multiple deletions or substitutions (in red letters) (D). WiELISA was performed to assess the inhibitory capacity of CipA deletion variants on the AP (B, E) and CP (C, F). NHS pre-incubated with the purified CipA proteins or BSA (500 nM for AP and 2.5 µM for the CP) were added to microtiter plates immobilized with LPS (AP) or IgM (CP). Formation of the MAC was detected by using a monoclonal anti-C5b-9 antibody. Data represent means and standard deviation of at least three different experiments, each conducted in triplicate. ****, p ≤ 0.0001, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%).CC BY · PubMed Central
Figure 2 Binding of CipA to different complement components of the AP and CP. Protein binding of C3 (A), C3b (B), C3c (C), C5 (D), C4b (E), FB (F), FD (G), and FH (H), respectively, to CipA to was measured by ELISA. CipA (5 ng/µl) was immobilized and incubated with 5 ng/µl purified complement components and BSA or gelatine were used as negative controls (ctrl). Bound complement components were detected using specific antisera (1:1,000). To assess statistical significance, two-tailed, unpaired Student’s t-test was performed. Data represent means and/or standard deviation of at least three different experiments, each conducted in at least triplicate. **, p ≤ 0.05; ****, p ≤ 0.0001; n.s., no statistical significance.
Figure 2 Binding of CipA to different complement components of the AP and CP. Protein binding of C3 (A), C3b (B), C3c (C), C5 (D), C4b (E), FB (F), FD (G), and FH (H), respectively, to CipA to was measured by ELISA. CipA (5 ng/µl) was immobilized and incubated with 5 ng/µl purified complement components and BSA or gelatine were used as negative controls (ctrl). Bound complement components were detected using specific antisera (1:1,000). To assess statistical significance, two-tailed, unpaired Student’s t-test was performed. Data represent means and/or standard deviation of at least three different experiments, each conducted in at least triplicate. **, p ≤ 0.05; ****, p ≤ 0.0001; n.s., no statistical significance.CC BY · PubMed Central
Figure 3 Impact of CipA on the enzymatic activity of the C5 convertases. The influence of CipA on the C5 convertase was analyzed by measuring the generation of C5a. The C5 convertases of the AP (A) and CP (B) were constituted on microtiter plates coated with LPS or IgM by adding NHS. Thereafter, reaction mixtures of C5 preincubated with or without CipA variants were added. The generation and release of C5a in the supernatant was then detected by C5a ELISA. Data represent means and standard deviation of at least three independent experiments, each conducted in duplicate. ***, p ≤ 0.0002; ****, p ≤ 0.0001, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%).
Figure 3 Impact of CipA on the enzymatic activity of the C5 convertases. The influence of CipA on the C5 convertase was analyzed by measuring the generation of C5a. The C5 convertases of the AP (A) and CP (B) were constituted on microtiter plates coated with LPS or IgM by adding NHS. Thereafter, reaction mixtures of C5 preincubated with or without CipA variants were added. The generation and release of C5a in the supernatant was then detected by C5a ELISA. Data represent means and standard deviation of at least three independent experiments, each conducted in duplicate. ***, p ≤ 0.0002; ****, p ≤ 0.0001, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%).CC BY · PubMed Central
Figure 4 Interaction of CipA with FI. Protein binding of FI to CipA was measured by ELISA (A). CipA-coated wells (5 ng/µl) were incubated with 5 ng/µl purified FI and protein complexes were detected using an anti-FI antibody (1:1,000). To assess statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%) was performed. Data represent means and standard deviation of at least three different experiments, each conducted in at least triplicate. ****, p ≤ 0.0001. Dose-dependent binding of FI to CipA (B). CipA (5 ng/µl) immobilized was incubated with increasing concentrations (0 to 25 nM) of purified FI and dissociation constant was approximated via non-linear regression, using a one-site, specific binding model. Data represent means and standard deviation of at least three different experiments, each conducted in triplicate. Detection of the FI-interacting region within CipA employing diverse CipA variants (C–E). Microtiter plates coated with CipA and CipA variants (5 ng/µl) were incubated with FI (10 ng/µl) and binding was detected by an anti-Fi antibody (1:1,000). BSA was used as negative control in all assays. Data represent means and standard deviation of at least three different experiments, each conducted in triplicate. **, p ≤ 0.05, ****, p ≤ 0.0001, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%).
Figure 4 Interaction of CipA with FI. Protein binding of FI to CipA was measured by ELISA (A). CipA-coated wells (5 ng/µl) were incubated with 5 ng/µl purified FI and protein complexes were detected using an anti-FI antibody (1:1,000). To assess statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%) was performed. Data represent means and standard deviation of at least three different experiments, each conducted in at least triplicate. ****, p ≤ 0.0001. Dose-dependent binding of FI to CipA (B). CipA (5 ng/µl) immobilized was incubated with increasing concentrations (0 to 25 nM) of purified FI and dissociation constant was approximated via non-linear regression, using a one-site, specific binding model. Data represent means and standard deviation of at least three different experiments, each conducted in triplicate. Detection of the FI-interacting region within CipA employing diverse CipA variants (C–E). Microtiter plates coated with CipA and CipA variants (5 ng/µl) were incubated with FI (10 ng/µl) and binding was detected by an anti-Fi antibody (1:1,000). BSA was used as negative control in all assays. Data represent means and standard deviation of at least three different experiments, each conducted in triplicate. **, p ≤ 0.05, ****, p ≤ 0.0001, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%).CC BY · PubMed Central
Figure 5 Structural prediction of CipA obtained with AlphaFold2. The mature CipA18-369 protein has a short, 11 amino acid-long unstructured N-terminus (A), followed by three approximately equally sized domains (B), recognized as META domain 1 (AA 46-107), META domain 2 (AA 151-253) and a C-terminal domain of unknown function, DUF4377 (AA 277-361). The DUF4377 domain is made up entirely of beta-sheets, the last of which contains the E360 residue in WT CipA (blue, E360 highlighted in yellow in (C) which was mutagenized to proline in the E360P mutant (beige, P360 highlighted in red in (C). Introduction of this amino acid disrupts the final beta-sheet strands and results in reorientation of the last 9 C-terminal amino acids (D), away from the DUF4377 domain, but without any overt effect on the other parts of the molecule.
Figure 5 Structural prediction of CipA obtained with AlphaFold2. The mature CipA18-369 protein has a short, 11 amino acid-long unstructured N-terminus (A), followed by three approximately equally sized domains (B), recognized as META domain 1 (AA 46-107), META domain 2 (AA 151-253) and a C-terminal domain of unknown function, DUF4377 (AA 277-361). The DUF4377 domain is made up entirely of beta-sheets, the last of which contains the E360 residue in WT CipA (blue, E360 highlighted in yellow in (C) which was mutagenized to proline in the E360P mutant (beige, P360 highlighted in red in (C). Introduction of this amino acid disrupts the final beta-sheet strands and results in reorientation of the last 9 C-terminal amino acids (D), away from the DUF4377 domain, but without any overt effect on the other parts of the molecule.CC BY · PubMed Central
Figure 6 CipA lacks intrinsic proteolytic activity on C3b and C4b and formation of a quadripartite complex to inactivate C3b and C4b. Intrinsic proteolytic activity of CipA in FI-mediated inactivation of C3b was assessed by Western blotting (A–C). CipA or BSA coated wells were incubated with C3b or with C3b and FI for 1 h (A) and 6 h (B) at RT or for 6 h at 37°C (C). After termination, C3b degradation products were visualized by Western blotting employing a polyclonal anti-C3 antibody. Detection of CipA (D) in reaction mixtures shown in (C) by using an anti-CipA antibody (23). Formation of a quadripartite complex results in inactivation of C3b (E) and C4b (F). Microtiter plates coated with CipA, CipA ΔE360-K369 or CipA E360P (5 ng/µl) were incubated in the absence (-FI) or presence of FI (+FI). Thereafter, reaction mixtures containing C3b and FH or C4b and C4BP were added to the wells and were then subjected to SDS-PAGE and Western blotting. C3b and C4b degradation products were visualized by using an anti-C3 antibody and a mixture containing an anti-C4 and anti-C4d antibody. Control reactions containing C3b, FI, and FH as well as C4b, FI, and C4BP.
Figure 6 CipA lacks intrinsic proteolytic activity on C3b and C4b and formation of a quadripartite complex to inactivate C3b and C4b. Intrinsic proteolytic activity of CipA in FI-mediated inactivation of C3b was assessed by Western blotting (A–C). CipA or BSA coated wells were incubated with C3b or with C3b and FI for 1 h (A) and 6 h (B) at RT or for 6 h at 37°C (C). After termination, C3b degradation products were visualized by Western blotting employing a polyclonal anti-C3 antibody. Detection of CipA (D) in reaction mixtures shown in (C) by using an anti-CipA antibody (23). Formation of a quadripartite complex results in inactivation of C3b (E) and C4b (F). Microtiter plates coated with CipA, CipA ΔE360-K369 or CipA E360P (5 ng/µl) were incubated in the absence (-FI) or presence of FI (+FI). Thereafter, reaction mixtures containing C3b and FH or C4b and C4BP were added to the wells and were then subjected to SDS-PAGE and Western blotting. C3b and C4b degradation products were visualized by using an anti-C3 antibody and a mixture containing an anti-C4 and anti-C4d antibody. Control reactions containing C3b, FI, and FH as well as C4b, FI, and C4BP.CC BY · PubMed Central
Figure 7 Recruitment of serum-derived FI to CipA mediates escape of A. baumannii from complement-mediated killing. CipA production in different A. baumannii strains was verified by Western blot analysis (A). CipA was detected in A. baumannii cell lysates (10 µg each) by using an anti-CipA antibody (1:100). Binding of FI to A. baumannii strains upon NHS incubation was assessed by Western blotting using an anti-FI antibody (1:1,000) (B). Survival of A. baumannii strains in human serum (C, D). 5 x 107 cells of A. baumannii ΔcipA::cipA (●), ΔcipA (▲), and ΔcipA::cipA E360P (■) were incubated in increasing amounts of human serum for 2 h at 37 °C, serially diluted and cfu counts determined. Cfu counts were related to controls incubated in LB medium instead of serum, for which survival was set at 100%. Shown are results from at least three independent experiments (C). Survival of A. baumannii strains at 50% NHS (D). **, p ≤ 0.002, ****, p ≤ 0.0001, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%). p; pellet; s, supernatant; w, final wash fraction, e; eluate fraction.
Figure 7 Recruitment of serum-derived FI to CipA mediates escape of A. baumannii from complement-mediated killing. CipA production in different A. baumannii strains was verified by Western blot analysis (A). CipA was detected in A. baumannii cell lysates (10 µg each) by using an anti-CipA antibody (1:100). Binding of FI to A. baumannii strains upon NHS incubation was assessed by Western blotting using an anti-FI antibody (1:1,000) (B). Survival of A. baumannii strains in human serum (C, D). 5 x 107 cells of A. baumannii ΔcipA::cipA (●), ΔcipA (▲), and ΔcipA::cipA E360P (■) were incubated in increasing amounts of human serum for 2 h at 37 °C, serially diluted and cfu counts determined. Cfu counts were related to controls incubated in LB medium instead of serum, for which survival was set at 100%. Shown are results from at least three independent experiments (C). Survival of A. baumannii strains at 50% NHS (D). **, p ≤ 0.002, ****, p ≤ 0.0001, n.s., no statistical significance, one-way ANOVA with post-hoc Bonferroni multiple comparison test (confidence interval = 95%). p; pellet; s, supernatant; w, final wash fraction, e; eluate fraction.CC BY · PubMed Central
Figure 8 Molecular mechanism of complement inactivation mediated by CipA (hypothetical). Schematic representation of the molecular mechanism of complement inactivation by generating a quadripartite complex consisting of CipA, FI, C3b, and FH or CipA, FI, C4b, and C4BP to down regulate the AP, CP, and LP. BM, bacterial membrane. The figure was created with BioRender.com.
Figure 8 Molecular mechanism of complement inactivation mediated by CipA (hypothetical). Schematic representation of the molecular mechanism of complement inactivation by generating a quadripartite complex consisting of CipA, FI, C3b, and FH or CipA, FI, C4b, and C4BP to down regulate the AP, CP, and LP. BM, bacterial membrane. The figure was created with BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. 10.1016/S1473-3099(17)30753-191 · doi:10.1016/s1473-3099(17)30753-191
  2. 10.21203/rs.3.rs-1032816/v1 · doi:10.21203/rs.3.rs-1032816/v1

Metadata

Authors
Ries, J. I., Heß, M., Nouri, N., Wichelhaus, T. A., Göttig, S., Falcone, F. H., & Kraiczy, P.
Affiliations
  • Goethe University Frankfurt (DE)
  • Justus-Liebig-Universität Gießen (DE)
Corresponding author
Kraiczy, Peter
Venue
Frontiers in Immunology
Publisher
openRxiv
Published
2022-02-17
Volume
13
Pages
942482-942482
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4288038175
Cited by
17
References
66
Citations by year
2026: 2 · 2025: 6 · 2024: 4 · 2023: 3 · 2022: 2
FWCI
1.43
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by)
Funders
Deutsche Forschungsgemeinschaft
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
Keywords
Acinetobacter baumannii, CIPA, complement resistance, complement inactivation, factor I, C3b, C4b, C5 convertase, plasminogen-binding protein, immune evasion, complement factor H, C4b-binding protein, multidrug resistance, nosocomial infections, protein-protein interaction
MeSH terms
Complement Activation, Fibrinogen, Humans, Complement Factor B, Acinetobacter baumannii, Complement C3-C5 Convertases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.